sur Evotec AG (NASDAQ:EVTCY)
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb
Evotec SE has achieved significant scientific progress within its strategic neuroscience collaboration with Bristol Myers Squibb. This milestone has triggered a research payment of USD 20 million to Evotec. The target-based programme has advanced to late pre-clinical development. This development contributes to the promising pipeline of neurodegeneration programmes generated by the partnership.
Initiated in December 2016, the collaboration aims to identify treatments for various neurodegenerative diseases. Approved drugs largely focus on symptom management, highlighting the need for therapies that can slow or prevent disease progression.
In September 2021, Bristol Myers Squibb in-licensed EVT8683 as BMS-986419. Following a successful Phase I study, a Phase II study is planned for 2024. The partnership was extended in March 2023 for an additional eight years.
Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, emphasized the progress in the pipeline and the commitment to patient care. The partnership continues to advance critical programmes aimed at delivering new therapeutic options for neurological disorders.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Evotec AG